Total, bioavailable and free 25-hydroxyvitamin D levels as functional indicators for bone parameters in healthy children

You Joung Heo, Yun Jeong Lee, Kyunghoon Lee, Jae Hyun Kim, Choong Ho Shin, Young Ah Lee, Junghan Song

1 Department of Pediatrics, Seoul National University Children’s Hospital, Seoul National University College of Medicine, Seoul, Korea,
2 Department of Laboratory Medicine, Seoul National University Bundang Hospital, Seoul National University College of Medicine, Seongnam, Korea,
3 Department of Pediatrics, Seoul National University Bundang Hospital, Seoul National University College of Medicine, Seongnam, Korea

* nina337@snu.ac.kr (YAL); songjhcp@snu.ac.kr (JS)

Abstract

Objectives

Vitamin D is essential for bone health. Not only total but also free 25-hydroxyvitamin D (25OHD) may contribute to bone mass. We sought to determine which vitamin D measure best reflected clinical and bone parameters in healthy children.

Methods

A cross-sectional study including 146 healthy children (71 boys, 9.5 ± 1.9 years) conducted at a tertiary medical center. We used a multiplex liquid chromatography-tandem mass spectrometry-based assay to simultaneously measure vitamin D metabolites. The bioavailable and free 25OHD (25OHD_{BioA} and 25OHD_{Free}) levels were calculated using the genotype-specific or genotype-constant affinity coefficients of vitamin D-binding proteins (yielding spe-25OHD_{BioA}, spe-25OHD_{Free}, con-25OHD_{BioA}, con-25OHD_{Free} respectively). The 25OHD_{Free} level was directly measured (m-25OHD_{Free}). Bone mineral content (BMC) and bone mineral density (BMD) were assessed via dual-energy X-ray absorptiometry.

Results

The total 25OHD (25OHD_{Total}), the two forms of 25OHD_{BioA}, the three forms of 25OHD_{Free}, and 24,25-dihydroxyvitamin D_{3} levels correlated with parathyroid hormone level (all p < 0.01). Serum 25OHD_{Total} and m-25OHD_{Free} levels were influenced by age, pubertal status, season, body mass index (BMI), daylight hours, and vitamin D intake (all p < 0.05). The con-25OHD_{BioA} and con-25OHD_{Free} levels better reflected pubertal status and daylight hours than did the spe-25OHD_{BioA} and spe-25OHD_{Free} levels (both p < 0.01). The association between the 25OHD_{Total} level and bone parameters varied according to the BMI (interaction p < 0.05). In 109 normal-weight children, the con-25OHD_{BioA} and con-25OHD_{Free} levels correlated with total body BMC and BMD (both p < 0.05), whereas the 25OHD_{Total} and 24,25-
choong ho shin · website: https://en.snu.ac.kr/research/units/institutes
the funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.

competing interests: the authors have declared that no competing interests exist.

abbreviations: 1,25ohd; 1,25-dihydroxyvitamin d; 24,25ohd; 24,25-dihydroxyvitamin d; 25ohd, 25-hydroxyvitamin d; 25ohdbioa, bioavailable 25ohd, 25ohdfree, free 25-ohd; 25ohdtotal, total 25ohd; alp, alkaline phosphatase; ba, bone age; bmc, bone mineral content; bcmf, z, z-score for total body bmc; bmd, bone mineral density; bmod, z, z-score for lumbar spine bmd; bmodt, z, z-score for total body bmd; bmodfinall, z, z-score for total body less head bmd; bmi, body mass index; ca, calcium; con-25ohdbioa, bioavailable 25ohd calculated using a vdbp genotype-constant affinity coefficient; con-25ohdtot, free 25ohd calculated using a vdbp genotype-constant affinity coefficient; cv, coefficient of variation; dri, daily recommended intake; dxa, dual-energy x-ray absorptiometry; elisa, enzyme-linked immunosorbent assay; fm, fat mass; iPTH, intact parathyroid hormone; lc-ms/ms, liquid chromatography-tandem mass spectrometry; lm, z-score for lean mass; m-25ohd, directly measured free 25ohd; p, phosphorus; spe-25ohdbioa, bioavailable 25ohd calculated using vdbp genotype-specific affinity coefficients; spe-25ohtot, free 25ohd calculated using vdbp genotype-specific affinity coefficients; sD, standard deviation; vdbp, vitamin d-binding protein; vDSP, vitamin D Standardization Program; VMR, vitamin d metabolite ratio; VIF, variance inflation factor.

Dihydroxyvitamin D₃ levels were associated with total body BMC (both p < 0.05). No such association was found in overweight or obese children.

conclusions

in healthy children, total, bioavailable, and free 25ohd levels comparably reflected lifestyle factors. in normal-weight children, the con-25ohd_bioa and con-25ohd_free, but not m-25ohd_free levels, reflected bone mass, as did the 25ohd_total level.

introduction

Vitamin D is the principal hormone regulating calcium (Ca) and bone homeostasis. Vitamin D is subject to stepwise hydroxylation in the liver and kidney, yielding 25-hydroxyvitamin D (25ohd) and 1,25-dihydroxyvitamin D (1,25ohd₂), respectively. Active 1,25ohd₂ binds to the vitamin D receptor (VDR) in target cells. CYP24A1 catabolizes 25ohd into inactive 24,25-dihydroxyvitamin D (24,25ohd₂), preventing intoxication caused by active vitamin D [1]. The 24,25ohd₂ level reflects VDR activity. Currently, the serum total 25ohd level (25ohd_total) is the standard biological marker of clinical vitamin D status.

Most circulating vitamin D is bound to vitamin D-binding protein (VDBP) (85–90%) or albumin (10–15%). Only a small proportion (less than 0.1%) is unbound or “free”. The bioavailable proportion of 25ohd (25ohd_bioa) is the sum of albumin-bound and free 25ohd (25ohd_free). VDBP is a highly polymorphic protein; over 120 variants have been described, but three major genotypes (Gc1f, Gc1s, and Gc2) predominate [2]. VDBP concentrations differed among subjects with six common Gc haplotypes [3], but the data on whether the binding affinity of VDBP for vitamin D metabolites varies by genotype [4], or not [5–7], are inconsistent. Either the genotype-specific or genotype-constant affinity coefficients of VDBP [4, 8] were used to yield spe-25ohd_free levels or con-25ohd_free levels employing appropriate formulae [9, 10]. Recently, an enzyme-linked immunosorbent assay (ELISA) was developed to directly measure 25ohd_free (m-25ohd_free).

It has been suggested that only small proportions of free hydrophobic molecules such as thyroid hormone and testosterone enter cells, and these are thus the biologically active hormones; this is the “free hormone” hypothesis [11]. This may be applicable to hydrophobic vitamin D [12]. However, this may not be relevant to bone health, as bone structural integrity relies on an adequate Ca supply delivered via the action of 1,25ohd₂ [13], principally VDBP-bound 25ohd [14]. A better [15–17] or poorer [18] association between bone mineral density (BMD) and 25ohd_free and/or 25ohd_bioa levels (compared to that of 25ohd_total) has been reported in adult populations. The vitamin D measure that best reflects bone parameters in healthy children remains unclear. As the vitamin D metabolite ratio (VMR) (i.e., that of 24,25ohd₂ to 25ohd_total) has been suggested to indicate bone health in adults [19], this needs to be investigated in children.

We previously reported that the 25ohd_total level (measured via radioimmunoassay) and adiposity both contributed to bone health in children [20]. Recently, we developed a multiplex liquid chromatography-tandem mass spectrometry (LC-MS/MS)-based assay to measure, simultaneously, multiple vitamin D metabolites [21]. Here, we measured the levels of total, bioavailable, and free 25ohd (either directly or via calculations), and the 24,25ohd₂ level. We then explored which measure best reflected clinical and bone parameters in healthy children.
Materials and methods

Subjects

We retrieved the demographic and blood test data of 146 healthy children who had visited Seoul National University Children’s Hospital between 2010 and 2011 to participate in a previous study (IRB no. H-1006-106-322) [20]. Sixty-seven visited in the winter (December 2010 through March 2011) and seventy-nine in the summer (June 2011 through September 2011). None had a previous history of chronic disease or any evidence of rickets, or was on any medication that might affect Ca or vitamin D status or bone metabolism. The study was approved by the institutional ethics committee of Seoul National University Hospital, which waived the need for informed consent (IRB no. H-2005-201-1127).

Physical examinations

Anthropometric measurements were performed in the pediatric endocrine clinic. A Harpenden stadiometer (Holtain Ltd., Crymych, United Kingdom) was used to measure height (cm) and a digital scale (model 150A; Cas Co. Ltd., Seoul, Korea) was used to measure weight (kg). The BMI was calculated as the weight (kg) divided by the square of the height (m²). Height, weight, and BMI Z-scores were determined [22], and the children were classified according to their BMI as normal (< 85th percentile), overweight (85th–95th percentile), or obese (≥ 95th percentile). All participants underwent physical examinations, including pubertal staging; bone age (BA) was assessed using the method of Greulich and Pyle.

Questionnaires exploring dietary intake and physical activity

Dietary and supplemental intakes of vitamin D and Ca were assessed by a dietitian on three different days using a food-frequency questionnaire. Dietary Ca intake was analyzed using CAN-pro 4.0 software (a computer-aided nutritional analysis program for professionals, the Korean Nutrition Society, Korea). Vitamin D contents were obtained from Rural Development Administration food composition tables [23]. Daily Ca and vitamin D intakes were categorized according to the following daily recommended intakes (DRIs) [24]: for Ca, 1,000 mg/day for boys aged 12–14 years, 900 mg/day for girls aged 12–14 years, 800 mg/day for boys and girls aged 9–11 years, and 700 mg/day for boys and girls aged 6–8 years; for vitamin D, 400 IU/day for those aged 12–18 years and 200 IU/day for those aged ≤ 11 years. Daylight outdoor hours and the time spent on physical activity were also assessed using the questionnaire. Regular physical activity was defined as moderate or vigorous physical activity for at least 60 min/day on at least 3 days of the week [25].

Biochemical assessments

Serum concentrations of Ca, phosphorus (P), alkaline phosphatase (ALP), and intact parathyroid hormone (iPTH) were measured, the latter using a standard ELISA-PTH immunoradiometric assay (CIS Bio International, Sorgues, France). The inter-assay coefficient of variation (CV) was 4.6% and the intra-assay CV was 4.3%. The normal range of serum Ca, P and iPTH were 8.8–10.5 mg/dL, 4.1–6.2 mg/dL, and 10–65 pg/mL. The normal range of serum ALP was as follows; for children aged 2 to 10 years, 146–367 IU/L for boys and 154–391 IU/L for girls; for those aged 11 to 13 years old, 152–438 IU/L for boys and 135–431 IU/L for girls.

Vitamin D metabolites were quantified and VDBP isoforms simultaneously identified via multiplex LC-MS/MS [21]. In brief, 25OHD₃, 25OHD₂, and 24,25OH₂D₃ levels were quantified in hexane extracts; trypsin digestion methods were used to quantify albumin and VDBP levels and to identify the VDBP isoforms. We combined two solutions in single wells to
measure all materials of interest simultaneously via LC-MS/MS. Deuterated D$_6$-25OHD$_3$, D$_6$-25OHD$_3$, D$_6$-24,25OHD$_2$D$_3$, and guinea pig serum served as the internal standards for the corresponding vitamin D metabolites, and VDBP and albumin, respectively. Pretreated samples were analyzed using an ACQUITY UPLC system (Waters, Milford, MA, USA) with an HSS T3 column (2.1 × 50 mm, 1.8 μm) coupled to a Xevo TQ-S mass analyzer (Waters) operating in multiple reaction monitoring mode. For all analytes, the bias and both CVs were less than ±10% for three quality control materials or ±20% at the lower limit of quantification. Levels of m-25OHD$_\text{Free}$ were obtained using ELISA (Diasource ImmunoAssays; Louvain-la-Neuve, Belgium). We defined vitamin D deficiency as a 25OHD$_\text{Total}$ concentration < 20 ng/mL [26]. Serum concentrations of 25OHD$_\text{Total}$ were calculated as the sum of the 25OHD$_2$ and 25OHD$_3$ levels. The 25OHD$_\text{BioA}$ and 25OHD$_\text{Free}$ levels were calculated using the circulating levels of 25OHD$_\text{Total}$, albumin, and VDBP, and the affinity coefficients of 25OHD for albumin and VDBP, employing appropriate formulae [9, 10]. The con-25OHD$_\text{BioA}$ and con-25OHD$_\text{Free}$ levels were derived by applying a particular affinity coefficient regardless of the VDBP genotype [8]. The VMR was the 24,25OHD$_2$D$_3$ level divided by the 25OHD$_\text{Total}$ level.

**Bone densitometry**

The body composition details (total-body bone mineral contents [BMC$_\text{TB}$], fat mass [FM], and lean mass [LM]), and the BMDs of total body (BMD$_\text{TB}$) and lumbar spine L1–L4 (BMD$_\text{LS}$) were measured using the Lunar Prodigy Advance DXA bone densitometer [General Electric (GE) Lunar Corporation, Madison, WI, USA] with a pediatric software (ver. enCORE 2005 9.15.010, GE Lunar Corp.). All measurements including each region of interest were carried out by a trained technician and underwent daily quality control assessment in accordance with the manufacturer’s standards. The BMD of total body less head (BMD$_\text{TBLH}$) was calculated via the total BMC of the trunk, upper limbs, and lower limbs, divided by the area of the same regions. The coefficients of variation for the BMD$_\text{TB}$, BMD$_\text{TBLH}$, and BMD$_\text{LS}$ of 30 children with repeated measurements were 0.87%, 0.77%, and 1.20%, respectively. The Z-scores for FM, LM, BMC$_\text{TB}$, BMD$_\text{TB}$, BMD$_\text{LS}$, and BMD$_\text{TBLH}$ (FM$_Z$, LM$_Z$, BMC$_\text{TB,Z}$, BMD$_\text{TB,Z}$, BMD$_\text{LS,Z}$, and BMD$_\text{TBLH,Z}$, respectively) were defined by the standard equation using age- and sex-matched reference values of Korean children and adolescents [27, 28]. The Z-scores were computed as follows, (measured values–matched reference mean) / matched reference standard deviation.

**Statistical analysis**

The Shapiro-Wilk test was used to assess normality; variables with skewed distributions were logarithmically transformed prior to analysis. Continuous variables are presented as the means ± standard deviations (SDs) or as medians (with interquartile ranges). Student’s t-test or the Mann-Whitney U-test was used to compare two groups. The Kruskal-Wallis test was employed to compare the six groups with different VDBP isoforms, and a Bonferroni-corrected p-value of 0.0033 was applied when performing multiple comparisons. Categorical variables are presented as frequencies (%) and were compared between two groups using the chi-squared test. Pearson correlation coefficients were derived to explore the associations of vitamin D metabolite levels with clinical and biochemical variables. Heterogeneity was evident with a significance of p < 0.05 when the interaction of BMI category (normal-weight vs. overweight or obese) with the effects of vitamin D metabolites on DXA parameters was evaluated by calculating interaction terms (BMI category × each vitamin D metabolite). Univariate and
multivariate regression analyses were performed to explore the relationships between vitamin D metabolite levels and bone density parameters yielded by DXA. Multicollinearity (which occurs when two predictors in a model are inter-related) was tested by employing variance inflation factor (VIF) statistics to evaluate age, sex, the FM_Z, the LM_Z, and vitamin D metabolite levels. No multicollinearity exists for a VIF score < 3. P < 0.05 was considered to reflect statistical significance. All analyses were performed with the aid of the SPSS software package ver. 25.0 for Windows (IBM Corp., Armonk, NY, USA).

**Results**

**Baseline characteristics of the participants**

The clinical and biochemical characteristics of the 146 children (71 boys and 75 girls, age range 5.0–13.5 years) are summarized in **Table 1**. The chronological age and BA were comparable, with mean values of 9.5 and 9.4 years, respectively. Forty-two (28.8%) were pubertal, Table 1. Clinical characteristics of the participants.

|                        | Total          | Boys           | Girls          |
|------------------------|----------------|----------------|----------------|
| Chronological age (years) | 9.5 ± 1.9 | 9.1 ± 1.5b | 9.9 ± 2.3b |
| Bone age (years)          | 9.4 ± 2.3 | 9.4 ± 1.8 | 9.3 ± 2.7 |
| Pubertal, n (%)           | 42 (28.8%) | 28 (37.3%)b | 14 (19.7%)b |
| Summer: Winter, n (%)     | 79:67 (54.1:45.9) | 41:34 (54.7:45.9) | 38:33 (53.5:46.5) |
| Height Z-score           | -0.3 ± 1.0 | 0.1 ± 1.2 | -0.1 ± 1.4 |
| Weight Z-score            | 0 ± 1.3 | 0 ± 1.2 | 0 ± 1.4 |
| BMI Z-score              | 0.2 ± 1.3 | 0.3 ± 1.2 | 0.1 ± 1.4 |
| Normal weight: overweight: obesity, n (%) | 109:14:23 (74.7:9.5:15.8) | 55:10:10 (73.3:13.3:13.3) | 54:4:13 (76.1:5:6:18.3) |
| Total 25-hydroxyvitamin D <20ng/mL, n (%) | 78 (53.4) | 39 (52.0) | 39 (54.9) |
| Vitamin D intake (IU/day)* | 670.2 ± 431.1 | 660.3 ± 325.0 | 680.9 ± 524.5 |
| Calcium intake (mg/day)*   | 630.7 ± 278.3 | 594.0 ± 246.2 | 670.2 ± 306.8 |
| Calcium intake ≥ DRI, n (%) | 29 (27.4) | 14 (25.5) | 15 (29.4) |
| Regular physical activity, n (%) | 59 (50.9) | 25 (42.4) | 34 (59.6) |
| Daylight outdoor hours/week* | 3.3 ± 2.6 | 3.4 ± 2.8 | 3.1 ± 2.4 |
| Serum calcium level (mg/dL)* | 9.7 ± 0.4 | 9.7 ± 0.4 | 9.7 ± 0.4 |
| Serum phosphorus level (mg/dL) | 5.2 ± 0.6 | 5.2 ± 0.5 | 5.2 ± 0.7 |
| Serum alkaline phosphatase level (IU/L)* | 250.6 ± 59.4 | 250.5 ± 56.9 | 250.59 ± 62.46 |
| Intact parathyroid hormone (pg/mL)* | 22.8 ± 10.6 | 23.3 ± 10.5 | 22.3 ± 10.8 |
| Fat mass Z-score           | 1.6 ± 2.7 | 1.8 ± 1.2 | 1.3 ± 2.6 |
| Lean mass Z-score          | -0.6 ± 1.7 | -0.1 ± 1.5b | -1.1 ± 1.3b |
| BMC_TB Z-score            | -0.2 ± 1.5 | -0.3 ± 1.4 | -0.2 ± 1.7 |
| BMD_TB Z-score            | 0.3 ± 1.3 | 0.2 ± 1.2 | 0.4 ± 1.3 |
| BMD_Ls Z-score            | -0.2 ± 1.1 | -0.2 ± 1.1 | -0.3 ± 1.1 |
| BMD_TBLH Z-score          | 0.1 ± 1.2 | 0.1 ± 1.2 | 0.1 ± 1.2 |

All continuous variables are described as the mean ± SD.

* Ln transformed.

b P-value < 0.05.

Abbreviation: ALP, alkaline phosphatase; BMI, body mass index; DRI, Daily recommended intake; BMC_TB, total body bone mineral content; BMD_TB, total body bone mineral density; BMD_Ls, lumbar spine bone mineral density; BMD_TBLH, total body less head bone mineral density.

Missing values for vitamin D intake (n = 32), calcium intake (n = 40), physical activity and daylight outdoor hour (n = 30), serum calcium, phosphorus, and alkaline phosphatase levels (n = 3).

https://doi.org/10.1371/journal.pone.0258585.t001
with a higher proportion of boys than girls (37.3% vs. 19.7%, p = 0.019). Overweight or obesity was evident in 14 (9.5%) and 23 (15.8%) subjects, respectively. Boys had a higher LM_Z than girls (−0.1 ± 1.5 vs. −1.1 ± 1.7, p < 0.001) but the FM_Z did not differ between the sexes. The proportion of vitamin D intake ≥ the DRI was higher in boys than in girls (93.2% vs. 80.8%, p = 0.034).

Vitamin D metabolite levels according to clinical and biochemical factors (Tables 2 and 3)

Vitamin D deficiencies were evident in 78 (53.4%) subjects, with no sex difference. The serum concentrations of Ca, P, ALP, and iPTH were within the normal ranges. The serum concentration of 25OHD_Total was 19.8 ± 1.3 ng/mL. The 25OHD_BioA levels were 2.6 ± 0.9 ng/mL for con-25OHD_BioA and 2.7 ± 1.3 ng/mL for spe-25OHD_BioA. The 25OHD_Free levels were 6.5 ± 2.3 pg/mL for con-25OHD_Free, 6.7 ± 3.5 pg/mL for spe-25OHD_Free, and 3.6 ± 1.3 pg/mL for m-25OHD_Free. The serum concentration of m-25OHD_Free was significantly correlated with the serum concentrations of 25OHD_Total (r = 0.655, p < 0.001), con-25OHD_Free (r = 0.610, p < 0.001), and spe-25OHD_Free (r = 0.334, p < 0.001). The serum concentration of 24,25OH₂D₃ was 1.1 ± 0.6 ng/mL. No between-sex differences were evident (Table 2).

Vitamin D deficiency was more prevalent in winter (p < 0.001 vs. summer), during puberty (p = 0.006 vs. prepuberty), and in overweight or obese subjects (p = 0.002 vs. normal-weight). Children who visited during summer exhibited higher levels of 25OHD_Total, the two forms of 25OHD_BioA, and the three forms of 25OHD_Free and 24,25OH₂D₃ than did those who visited during winter (all p < 0.001). The serum concentrations of 25OHD_Total, con-25OHD_BioA, con-25OHD_Free, m-25OHD_Free, and 24,25OH₂D₃ were significantly lower during puberty than during prepuberty (all p < 0.01), and in those who were overweight or obese (compared to subjects of normal weight) (all p < 0.01). In terms of Ca intake, no significant difference in any vitamin D metabolite was evident between those of ≥ DRI or < DRI status. In terms of vitamin D intake, children with intakes above the DRI exhibited higher m-25OHD_Free levels than did others (p = 0.021). Children who engaged in regular physical activity had higher levels of con-25OHD_Free and m-25OHD_Free than did others (p < 0.05 for both). No significant difference in either the VDBP or VMR*100 according to any clinical factor was apparent (Table 2).

The older the subject, the lower the 25OHD_Total and m-25OHD_Free levels (p < 0.05 for both). The higher the BMI Z-score, the lower the levels of 25OHD_Total, the two forms of 25OHD_BioA, and the three forms of 25OHD_Free and 24,25OH₂D₃ (all p < 0.05). Vitamin D intake was positively correlated with 25OHD_Total and m-25OHD_Free levels (p < 0.05 for both). Daylight outdoor hours were positively associated with 25OHD_Total, con-25OHD_BioA, con-25OHD_Free, m-25OHD_Free, 24,25OH₂D₃, and VMR*100 levels (all p < 0.01, Table 3). The levels of 25OHD_Total, the two forms of 25OHD_BioA, and the three forms of 25OHD_Free and 24,25OH₂D₃ were negatively correlated with serum iPTH levels (all p < 0.01, Fig 1) and the serum P level (all p < 0.01).

Vitamin D metabolites according to VDBP isoform

The Gc1f/Gc1f isoform was the most prevalent (n = 46, 31.5%), followed by the Gc1f/Gc1s (n = 29, 19.9%), Gc1f/Gc2 (n = 29, 19.9%), Gc1s/Gc1s (n = 15, 10.3%), Gc2/Gc2 (n = 14, 9.6%), and Gc1s/Gc2 (n = 13, 8.9%) isoforms (S1 Table). VDBP concentrations differed across the six isoforms (p = 0.011 via the Kruskal-Wallis test, Fig 2A), but 25OHD_Total levels did not (Fig 2B). VDBP concentrations were significantly lower in children with the Gc2/Gc2 isoform than in those with the Gc1f/Gc1f, Gc1f/Gc1s, Gc1f/Gc2, or Gc1s/Gc2 isoform, as revealed after
| Vitamin D deficiency | Total (n) | Bioavailable 25-hydroxyvitamin D (calculated, genotype constant or specific, and directly measured) | Vitamin D metabolites calculated using VDBP genotype-specific affinity coefficients | 25-hydroxyvitamin D calculated using VDBP genotype-specific affinity coefficients |
|----------------------|----------|-------------------------------------------------------------------------------------------------|-------------------------------------------------------------------------------------|--------------------------------------------------------------------------------|
| No Vitamin D deficiency | 146 (138.3%) | 26.1±0.9 | 6.7±3.3 | 6.1±2.3 | 11.1±0.6 | 5.6±2.0 | 226.5±57.9 |
| Boys | 75 (80.0%) | 26.1±0.9 | 6.7±3.3 | 6.1±2.3 | 11.1±0.6 | 5.6±2.0 | 226.5±57.9 |
| Girls | 71 (88.4%) | 26.1±0.9 | 6.7±3.3 | 6.1±2.3 | 11.1±0.6 | 5.6±2.0 | 226.5±57.9 |
| Season | Summer | 79 (95.3%) | 22.7±5.9 | 7.8±3.7 | 7.6±2.1 | 4.1±1.3 | 0.7±0.5 | 226.3±52.3 |
| Winter | 67 (100%) | 22.7±5.9 | 7.8±3.7 | 7.6±2.1 | 4.1±1.3 | 0.7±0.5 | 226.3±52.3 |
| Puberty | Prepubertal | 104 (89.7%) | 20.9±5.5 | 6.2±3.7 | 6.1±2.3 | 11.1±0.6 | 5.6±2.0 | 226.5±57.9 |
| Pubertal | 42 (100%) | 20.9±5.5 | 6.2±3.7 | 6.1±2.3 | 11.1±0.6 | 5.6±2.0 | 226.5±57.9 |
| Normal weight | 109 (100%) | 21.1±6.2 | 7.1±5.6 | 7.0±2.3 | 3.8±1.2 | 5.7±1.4 | 226.5±57.9 |
| Overweight or obesity | 7 (50%) | 21.1±6.2 | 7.1±5.6 | 7.0±2.3 | 3.8±1.2 | 5.7±1.4 | 226.5±57.9 |
| DRI intakes below DRI | 24 (100%) | 20.4±5.5 | 6.4±3.7 | 6.1±2.3 | 11.1±0.6 | 5.6±2.0 | 226.5±57.9 |
| No physical activity | 52 (100%) | 20.4±5.5 | 6.4±3.7 | 6.1±2.3 | 11.1±0.6 | 5.6±2.0 | 226.5±57.9 |
| Yes | 57 (100%) | 20.4±5.5 | 6.4±3.7 | 6.1±2.3 | 11.1±0.6 | 5.6±2.0 | 226.5±57.9 |

All continuous variables are described as the mean ± SD.

*p values were calculated using a one-way ANOVA for continuous variables and the chi-square test for categorical variables.

Abbreviations:
- 25OHD: 25-hydroxyvitamin D
- D3: vitamin D
- VDBP: vitamin D-binding protein
- DRI: Daily Reference Intake

https://doi.org/10.1371/journal.pone.0258585.t002

Table 2. Comparison of vitamin D metabolites according to clinical factors.
Table 3. Correlation of clinical and biochemical factors with vitamin D metabolites.

|                          | No   | Total 25-hydroxyvitamin D (ng/mL) | Bioavailable 25-hydroxyvitamin D (calculated, genotype constant or specific) | Free 25-hydroxyvitamin D (calculated, genotype constant or specific, and directly-measured) | 24,25-dihydroxyvitamin D$_3$ (ng/mL) | Vitamin D metabolites ratio’100 | Vitamin D binding protein (µg/mL) |
|--------------------------|------|-----------------------------------|-----------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------|--------------------------------------|--------------------------------|----------------------------------|
| Age                      | 146  | -0.166$^b$                        | 0.024                                                                 | -0.112                                                                                         | 0.028                                                                 | -0.099                               | -0.185$^b$                     | -0.143                         | -0.022                         | -0.140                         |
| BMI Z-score              | 146  | -0.252$^c$                        | 0.024                                                                 | -0.189$^b$                                                                                     | 0.028                                                                 | -0.183$^b$                         | -0.216$^c$                     | -0.277$^c$                    | -0.311$^d$                    | -0.143                         | -0.035                         |
| Vitamin D intake$^a$     | 114  | 0.203$^b$                         | 0.153                                                                 | 0.152                                                                                          | 0.171                                                                 | 0.174                               | 0.275$^c$                      | 0.181                         | 0.12                           | 0.02                           |
| Calcium intake$^a$       | 106  | -0.06                             | -0.154                                                                | -0.104                                                                                         | -0.143                                                                 | -0.088                               | -0.027                         | -0.067                         | -0.04                         | 0.069                         |
| Daylight outdoor hours/ week$^d$ | 116  | 0.397$^c$                         | 0.163                                                                 | 0.319$^d$                                                                                     | 0.173                                                                 | 0.318$^d$                           | 0.340$^d$                      | 0.396$^d$                     | 0.286$^c$                     | 0.109                         |
| Calcium (mg/dL)$^a$      | 143  | 0.049                             | 0.014                                                                 | 0.064                                                                                          | -0.042                                                                 | -0.013                               | -0.059                         | 0.075                         | 0.051                         | 0.109                         |
| Phosphorus (mg/dL)       | 143  | -0.392$^d$                        | -0.227$^c$                                                            | -0.376$^d$                                                                                     | -0.254$^c$                                                                 | -0.396$^d$                           | -0.332$^d$                     | -0.38$^d$                      | -0.059                        | 0.081                         |
| Alkaline phosphatase (IU/L)$^a$ | 143  | -0.032                            | 0.088                                                                 | 0.005                                                                                          | 0.063                                                                 | -0.024                               | -0.115                         | -0.106                        | -0.119                        | -0.026                         |
| Intact parathyroid hormone (pg/mL)$^a$ | 146  | -0.347$^d$                        | -0.281$^d$                                                            | -0.311$^d$                                                                                     | -0.276$^d$                                                                 | -0.296$^d$                           | -0.246$^c$                     | -0.296$^d$                    | -0.018                        | -0.054                         |

Pearson correlation coefficient, r, are shown in table for each pair of variables listed.

$^a$ Ln transformed.

$^b$ P < 0.05

$^c$ P < 0.01

$^d$ P < 0.001.

Abbreviation: Spe-25OHD$_{BioA}$, bioavailable 25-hydroxyvitamin D calculated using vitamin D-binding protein (VDBP) genotype-specific affinity coefficients; Con-25OHD$_{BioA}$, bioavailable 25-hydroxyvitamin D calculated using a VDBP genotype-constant affinity coefficient; Spe-25OHD$_{free}$, free 25-hydroxyvitamin D calculated using VDBP genotype-specific affinity coefficients; Con-25OHD$_{free}$, free 25-hydroxyvitamin D calculated using a VDBP genotype-constant affinity coefficient; M-25OHD$_{free}$, directly measured free 25-hydroxyvitamin D; 24,25OH$_2$D$_3$.  

https://doi.org/10.1371/journal.pone.0258585.t003
Free 25-hydroxyvitamin D in healthy children

(A) Box plot comparing IP/TH levels between Total 25OHD < 20 ng/mL (n=78) and Total 25OHD ≥ 20 ng/mL (n=68).

(B) Scatter plot showing a negative correlation between IP/TH and Total 25OHD, with r = -0.347, p < 0.001.

(C) Scatter plot showing a negative correlation between IP/TH and Specific affinity-free 25OHD, with r = -0.276, p = 0.001.

(D) Scatter plot showing a negative correlation between IP/TH and Constant affinity-free 25OHD, with r = -0.296, p < 0.001.

(E) Scatter plot showing a negative correlation between IP/TH and Measured free 25OHD, with r = -0.246, p = 0.003.

(F) Scatter plot showing a negative correlation between IP/TH and 24,25OH₂D₃, with r = -0.296, p < 0.001.
the Bonferroni correction with p = 0.0033 (Fig 2A). As expected, the spe-25OHD_{BioA} and spe-25OHD_{Free} levels differed significantly across the six VDBP isoforms (p < 0.001 for both using the Kruskal-Wallis test); higher levels of spe-25OHD_{BioA} and spe-25OHD_{Free} (Fig 2C) were evident in children with the Gc2/Gc2 isoform than in those with the Gc1f/Gc1f, Gc1f/Gc1s, or Gc1f/Gc2 isoform, as revealed after the Bonferroni correction with p = 0.0033. However, levels of con-25OHD_{BioA}, con-25OHD_{Free} (Fig 2D), m-25OHD_{Free} (Fig 2E), and 24,25OH_{2}D_{3} (Fig 2F) did not differ across the six VDBP isoforms.

**Vitamin D metabolites and bone health parameters**

We found no significant interaction of sex with the effects of 25OHD_{Total} on BMC_{TB-Z}, BMD_{TB-Z}, BMD_{LS-Z}, or BMC_{TBLH-Z}. The interactions of BMI category with the effects of 25OHD_{Total} on BMC_{TBLH-Z} and BMD_{TB-Z} were significant (p < 0.05 for both, S1 Fig); we thus separately analyzed the normal weight and overweight or obese groups. FM_{Z} was positively associated with bone parameters (p < 0.01 for BMC_{TB-Z}, BMD_{LS-Z}, and BMC_{TBLH-Z} in the normal weight group; and p < 0.01 for BMC_{TB-Z} in the overweight or obese group). LM_{Z} was positively related to bone parameters (p < 0.001 for BMC_{TB-Z} and BMC_{TBLH-Z} in the normal weight group; and p < 0.05 for BMC_{TB-Z}, BMD_{TB-Z}, and BMC_{TBLH-Z} in the overweight or obese group, S2 Table). A multivariate-adjusted model was used to identify which vitamin D metabolite optimally explained the bone parameters, after adjusting for age, sex, FM_{Z}, and LM_{Z}. In the normal weight group, vitamin D deficiency and the 25OHD_{Total}, con-25OHD_{BioA}, con-25OHD_{Free}, and 24,25OH_{2}D_{3} levels were significantly predictive of BMC_{TBLH-Z} (all p < 0.05), with similar R² levels (0.58–0.62) (Table 4). However, no associations between the level of any vitamin D metabolite and BMC_{TBLH-Z} were found in the overweight or obese group (S3 Table). The con-25OHD_{BioA} and con-25OHD_{Free} levels were significantly predictive of BMC_{TB-Z} (p < 0.05 for both), with similar R² levels (0.16–0.13), in the normal weight group (Table 4), but no vitamin D metabolite level was related to BMC_{TB-Z} in the overweight or obese group (S3 Table). No vitamin D metabolite was associated with BMC_{LS-Z} or BMC_{TBLH-Z} in either group.

**Discussion**

In healthy children, all 25OHD measures inversely correlated with the serum iPTh level. The serum concentrations of 25OHD_{Total} and m-25OHD_{Free} reflected age, pubertal status, season, BMI category, daylight outdoor hours, and vitamin D intake. The con-25OHD_{BioA} and con-25OHD_{Free} levels better reflected pubertal status and daylight outdoor hours than did the spe-25OHD_{BioA} and spe-25OHD_{Free} levels. Of the bone parameters of healthy normal-weight children, the 25OHD_{Total}, con-25OHD_{BioA}, con-25OHD_{Free} and 24,25OH_{2}D_{3} levels were all similarly predictive of BMC_{TB-Z}, whereas both the con-25OHD_{BioA} and con-25OHD_{Free} levels were additionally associated with the BMC_{TB-Z}.

The methods used to quantify circulating metabolites vary among laboratories, which can lead to potential misclassifications of vitamin D status. VDBP measurements are strongly
Fig 2. Vitamin D metabolite levels across VDBP isoforms. Box-and-whisker plots of the concentrations of (A) VDBPs, (B) total 25OHD, (C) spe-25OHD<sub>free</sub>, (D) con-25OH<sub>2</sub>H<sub>2</sub>D<sub>3</sub>, (E) m-25OHD<sub>free</sub>, and (F) 24,25OH<sub>2</sub>D<sub>3</sub>. The thick lines in the boxes indicate the medians. The top and bottom lines indicate the 75<sup>th</sup> and 25<sup>th</sup> quartiles, respectively. The whiskers indicate the maximum and minimum values, with the exceptions of outliers (circles) and extremes (triangles). All outliers were at
influenced by the assays employed. For example, a monoclonal ELISA underestimated the level of a specific genotype (GcIf) [29]. In an attempt to standardize 25OHD assays, the Vitamin D Standardization Program (VDSP) was established in 2010. As our LC-MS/MS-based 25OHD quantification meets the VDSP criteria [30, 31], we used this assay to simultaneously measure multiple vitamin D metabolites and the VDBP isoforms [21]. The allele frequencies obtained were comparable to those from genotyping [32]. Directly measured 25OHD levels were significantly lower than the calculations, as in previous reports [21, 33]. These differences may reflect the lack of 25OHD measurement standardization.

Table 4. Multivariate regression analysis for vitamin D metabolites and bone health parameters in normal weight children.

| Vitamin D deficiency | BMC<sub>TB</sub> Z-score beta (SE) | R<sup>2</sup> | BMC<sub>TBLH</sub> Z-score beta (SE) | R<sup>2</sup> |
|----------------------|-----------------------------------|----------|-----------------------------------|----------|
| Con-25OHD<sub>Total</sub> (ng/mL) | 0.205 (0.078) | 0.587 | 0.300 (0.117)* | 0.155 |
| Spe-25OHD<sub>Total</sub> (ng/mL) | 0.044 (0.050) | 0.562 | 0.121 (0.074)* | 0.123 |
| Con-25OHD<sub>Free</sub> (pg/mL) | 0.017 (0.019) | 0.563 | 0.039 (0.028) | 0.117 |
| M-25OHD<sub>Free</sub> (pg/mL) | 0.134 (0.055) | 0.583 | 0.070 (0.085) | 0.107 |
| 24,25OHD<sub>D</sub><sub>3</sub> (ng/mL) | 0.281 (0.124)* | 0.58 | 0.274 (0.189) | 0.119 |
| Vitamin D metabolites ratio<sup>100</sup> | 0.084 (0.049) | 0.571 | 0.102 (0.074) | 0.117 |

Adjusted for age, sex, fat mass Z-scores, lean mass Z-scores.

* P-value < 0.05
b P-value ≤ 0.01.

Abbreviation: 25OHD<sub>Total</sub>, total 25-hydroxyvitamin D; Spe-25OHD<sub>BioA</sub>, bioavailable 25-hydroxyvitamin D calculated using vitamin D-binding protein (VDBP) genotype-specific affinity coefficients; Con-25OHD<sub>BioA</sub>, bioavailable 25-hydroxyvitamin D calculated using a VDBP genotype-constant affinity coefficient; Spe-25OHD<sub>Free</sub>, free 25-hydroxyvitamin D calculated using VDBP genotype-specific affinity coefficients; Con-25OHD<sub>Free</sub>, free 25-hydroxyvitamin D calculated using a VDBP genotype-constant affinity coefficient; M-25OHD<sub>Free</sub>, directly measured free 25-hydroxyvitamin D; 24,25OHD<sub>D</sub><sub>3</sub>, 24,25-dihydroxyvitamin D<sub>3</sub>; BMC<sub>TB</sub>, total body bone mineral content; BMC<sub>TBLH</sub>, total body bone mineral density; BMD<sub>LS</sub>, lumbar spine bone mineral density; BMD<sub>TBLH</sub>, total body less head bone mineral density.

https://doi.org/10.1371/journal.pone.0258585.t004
In healthy children, all 25OHD\textsubscript{BioA}, 25OHD\textsubscript{Free} and 24,25OHD\textsubscript{3} measures and 25OHD\textsubscript{Total} levels were comparably associated with serum iPTH levels. In terms of clinical factors, the m-25OHD\textsubscript{Free} and 25OHD\textsubscript{Total} levels better correlated with age, pubertal status, season, BMI category, daylight outdoor hours, and vitamin D intake than did other 25OHD measures. The con-25OHD\textsubscript{BioA} and con-25OHD\textsubscript{Free} levels, but not the spe-25OHD\textsubscript{BioA} and spe-25OHD\textsubscript{Free} levels, reflected pubertal status and daylight outdoor hours. In adults, the major determinants of 25OHD levels are exposure to sunlight and adiposity \cite{34}. Seasonal and sex differences in 25OHD levels were explained by sunlight exposure, outdoor activities, and dressing habits, although we found no sex difference in the present work. Levels of 25OHD decrease with age; lower levels after puberty are explained by increasing adiposity and demands for Ca and vitamin D during the pubertal growth spurt and bone remodeling \cite{35}. The inverse relationship between the 25OHD level and adiposity reflects the increased volume of distribution \cite{36} and the proinflammatory status caused by obesity \cite{37}. VDBP concentrations may vary according to estrogen exposure or liver or kidney disease \cite{38}, although we found no differences in VDBP concentration based on sex or pubertal status.

Six common Gc haplotypes affect serum VDBP and 25OHD\textsubscript{Total} levels; these encode the major carrier proteins of circulating 25OHD in both children \cite{39} and adults \cite{3}. We found that the serum VDBP concentrations differed across the six VDBP isoforms; however, neither the 25OHD\textsubscript{Total} nor the m-25OHD\textsubscript{Free} level was affected. Although VDBP is the major carrier of 25OHD\textsubscript{Total}, it remains unclear whether VDBP affinity for the 25OHD is genotype-specific \cite{4–7}. Three laboratories reported no significant differences in the affinities of the VDBP isoforms \cite{5–7}. Indeed, the amino-acid modifications in the Gc variants are unlikely to affect the cleft in the vitamin D-binding domain; thus, the Gc variants may not differ from others in terms of binding affinity \cite{40}. Although one study in adults reported small differences in m-25OHD\textsubscript{Free} levels according to VDBP haplotype \cite{3}, the m-25OHD\textsubscript{Free} level did not differ according to Gc haplotype in our present study, in line with previous reports on children \cite{41} and adults \cite{42}.

The “free hormone hypothesis” suggests that the small free fraction of 25OHD plays a pivotal role in terms of physiological activity and that VDBP-bound material serves as a reservoir of 25OHD\textsubscript{Total}. A woman with a bi-allelic deletion of Gc exhibited a very low level of 25OHD\textsubscript{Total} and congenital absence of VDBP, but remained normocalcemic, thus exhibiting relatively mild disruption of bone metabolism, supporting the “free hormone hypothesis” \cite{43}. However, the significance of the relationships between the various 25OHD measures and bone parameters varied by subject age, sex, hormonal and medication status, the methods used to measure vitamin D or VDBP, and the BMD measurement sites \cite{15–18, 44}. In racially diverse athletic men, Allison et al. reported better associations between con-25OHD\textsubscript{BioA} level derived using a monoclonal VDBP and BMDs at all sites compared to those of the 25OHD\textsubscript{Total} level \cite{17}. In postmenopausal women, Johnsen et al. showed that the spe-25OHD\textsubscript{BioA} and spe-25OHD\textsubscript{Free} levels derived using VDBP measured by an in-house radioimmunoassay correlated better with the total body and hip BMDs than did the 25OHD\textsubscript{Total} level only in those not taking Ca or vitamin D supplements \cite{15}. Jemielita et al. found a significant relationship between the spe-25OHD\textsubscript{BioA} and the BMD of the lumbar spine in black adults when the monoclonal VDBP assay was used, but not when employing polyclonal antibodies, nor in white participants, nor at other sites \cite{44}. When 25OHD\textsubscript{Free} levels were directly measured, Chhantyal et al. \cite{16} reported associations between the level of m-25OHD\textsubscript{Free} but not 25OHD\textsubscript{Total} and the lumbar BMD and the osteoporotic vertebral fracture rate in an older population. Michaëlsson et al. \cite{18} found a relationship between the 25OHD\textsubscript{Total} level, but not that of m-25OHD\textsubscript{Free} with BMD at any site in older Swedish women only during summer.
To the best of our knowledge, this is the first study to explore whether 25OHD\textsubscript{BioA} or 25OHD\textsubscript{Free} is the better index of vitamin D status in terms of BMD and BMC compared to 25OHD\textsubscript{Total} in healthy children. In this study, BMC\textsubscript{TB\_Z} was similarly related to the 25OHD\textsubscript{Total}, con-25OHD\textsubscript{BioA}, and con-25OHD\textsubscript{Free} levels, but not the m-25OHD\textsubscript{Free} level, and the con-25OHD\textsubscript{BioA} and con-25OHD\textsubscript{Free} levels were related to BMD\textsubscript{TB\_Z}. Our inconsistent results do not afford sufficient evidence to confirm the “free hormone hypothesis”, the validity of which for vitamin D has been questioned [18]. The effects of 1,25(OH)\textsubscript{2}D on bone homeostasis are mediated principally via an adequate Ca supply ensured by indirect action of 1,25(OH)\textsubscript{2}D on the intestine and kidney [13, 45]. Direct effects of 1,25(OH)\textsubscript{2}D on the osteoblastic lineage were subtle when the Ca supply was adequate [46]. As renal VDBP-bound 25OHD is taken up via the megalin/cubulin complex, this material (rather than free 25OHD) is the major entry pathway to the generation of 1,25(OH)\textsubscript{2}D [14]; any contribution of free 25OHD to bone health may be subtle. The other evidence against the “free hormone hypothesis” is that VDBP-null mice were protected against (rather than sensitized to) vitamin D toxicity [18, 47].

Although measurements of 25OHD\textsubscript{Free} and VDBP have not yet been standardized, two earlier studies compared two sets of calculated 25OHD\textsubscript{Free} figures (genotype-constant and genotype-specific). The spe-25OHD\textsubscript{Free} level correlated better with the total body and hip BMDs than did the con-25OHD\textsubscript{Free} level in postmenopausal women [15], whereas the spe-25OHD\textsubscript{Free} level correlated more poorly with the BMI and metabolic indices than did the con-25OHD\textsubscript{Free} or m-25OHD\textsubscript{Free} level in healthy children. [41]. In our healthy children, the con-25OHD\textsubscript{Free} level better correlated with the total body BMD and BMC than did the spe-25OHD\textsubscript{Free} or m-25OHD\textsubscript{Free} level. Together, the pediatric data indicate that the con-25OHD\textsubscript{Free} level adequately reflects the bone and metabolic parameters of healthy children.

The 24,25(OH)\textsubscript{2}D\textsubscript{3} level also reflected BMC\textsubscript{TB\_Z} in our healthy children, but the calculated VMR was not correlated with any clinical factor or bone parameter. The serum 24,25(OH)\textsubscript{2}D level was lower in adult patients with chronic kidney disease, which was suggestive of decreases in vitamin D catabolism and VDR activity, and reduced 1,25(OH)\textsubscript{2}D production, the level of which better correlated with the serum PTH level than did either the 25OHD or 1,25(OH)\textsubscript{2}D level [48]. In elderly patients with diabetes, hypertension, or chronic kidney disease, the 24,25(OH)\textsubscript{2}D level and VMR better correlated with hip fracture than did the 25OHD\textsubscript{Total} level [49].

Our study had some limitations. First, the cross-sectional design did not allow us to assess the cumulative effects over time of 25OHD metabolites on BMC or BMD changes during puberty. Second, although we included overweight or obese children, the sample size was too small to allow us to identify risk factors associated with bone parameters. Third, we did not measure biologically active 1,25(OH)\textsubscript{2}D levels; these vary widely because the 1,25(OH)\textsubscript{2}D half-life is only approximately 4 h. A strength of the study is that we simultaneously measured multiple 25OHD metabolites using an LC-MS/MS-based assay to determine which vitamin D metabolite optimally reflected bone health in healthy children.

**Conclusion**

In healthy normal-weight children, the con-25OHD\textsubscript{BioA} and con-25OHD\textsubscript{Free} levels similarly reflected the BMC\textsubscript{TB} as did the 25OHD\textsubscript{Total} level, and additionally correlated with the BMD\textsubscript{TB}. However, the spe-25OHD\textsubscript{BioA}, spe-25OHD\textsubscript{Free}, and m-25OHD\textsubscript{Free} levels were not associated with bone parameters. The calculated 25OHD\textsubscript{Free} (without adjustment for VDBP genotypes) was superior to the 25OHD\textsubscript{Free} measured by ELISA in terms of identifying bone parameters among healthy children. The 25OHD measures optimally reflecting bone and metabolic health in children with chronic diseases require further evaluation.
Supporting information

S1 Fig. Difference in correlation of total 25OHD with Z-scores of total body BMC and BMD among normal weight and overweight or obese children. (A) A positive correlation between total 25OHD level and Z-score for total body BMC and BMD in normal weight children. (B) A negative correlation between total 25OHD level and Z-score for total body BMC and BMD in overweight or obese children (P value for interaction 0.005 for BMC Z-score and P value for interaction 0.020 for total body BMD Z-score) Abbreviation: 25OHD, 25-hydroxyvitamin D; BMC, bone mineral content; BMD, bone mineral density.

(TIF)

S1 Table. Frequency of VDBP isoforms in healthy Korean children and their vitamin D metabolites concentration.

(DOCX)

S2 Table. Univariate regression analysis between vitamin D metabolites and bone health parameters.

(DOCX)

S3 Table. Multivariate linear regression analysis to evaluate association between vitamin D metabolites and bone health parameters in overweight and obese children (n = 37).

(DOCX)

Acknowledgments

The authors especially thank Sun-Hee Jun and Jeong Seon Lee for sample preparation and analysis.

Author Contributions

Conceptualization: Choong Ho Shin, Young Ah Lee, Junghan Song.

Formal analysis: You Joung Heo.

Funding acquisition: Choong Ho Shin, Junghan Song.

Methodology: Kyunghoon Lee, Junghan Song.

Supervision: Choong Ho Shin, Young Ah Lee, Junghan Song.

Writing – original draft: You Joung Heo.

Writing – review & editing: Yun Jeong Lee, Jae Hyun Kim, Young Ah Lee, Junghan Song.

References

1. Cavalier E, Souberbielle JC. Vitamin D and its metabolites: from now and beyond. Ejifcc. 2018; 29(2):105–10. PMID: 30050393

2. Cleve H, Constans J. The mutants of the vitamin-D-binding protein: more than 120 variants of the GC/DBP system. Vox Sang. 1988; 54(4):215–25. https://doi.org/10.1111/j.1423-0410.1988.tb03908.x PMID: 3388819

3. Schwartz JB, Gallagher JC, Jorde R, Berg V, Walsh J, Eastell R, et al. Determination of Free 25(OH)D Concentrations and Their Relationships to Total 25(OH)D in Multiple Clinical Populations. J Clin Endocrinol Metab. 2018; 103(9):3278–88. https://doi.org/10.1210/jc.2018-00295 PMID: 29955795

4. Arnaud J, Constans J. Affinity differences for vitamin D metabolites associated with the genetic isoforms of the human serum carrier protein (DBP). Hum Genet. 1993; 92(2):183–8. https://doi.org/10.1007/BF00219689 PMID: 8370586
5. Kawakami M, Imawari M, Goodman DS. Quantitative studies of the interaction of cholecalciferol (vitamin D3) and its metabolites with different genetic variants of the serum binding protein for these sterols. Biochem J. 1979; 179(2):413–23. https://doi.org/10.1042/bj1790413 PMID: 90502

6. Bouillon R, van Baalen H, de Moor P. Comparative study of the affinity of the serum vitamin D-binding protein. J Steroid Biochem. 1980; 13(9):1029–34. https://doi.org/10.1016/0022-4731(80)90133-8 PMID: 6893475

7. Boutin B, Gaibraith RM, Arnaud P. Comparative affinity of the major genetic variants of human group-specific component (vitamin D-binding protein) for 25-(OH) vitamin D. J Steroid Biochem. 1989; 32(1a):59–63. https://doi.org/10.1016/0022-4731(89)90014-9 PMID: 2913402

8. Bikle DD, Gee E, Halloran B, Kowalski MA, Ryzen E, Haddad JG. Assessment of the free fraction of 25-hydroxyvitamin D in serum and its regulation by albumin and the vitamin D-binding protein. J Clin Endocrinol Metab. 1986; 63(4):945–9. https://doi.org/10.1210/jcem-63-4-954 PMID: 3745048

9. Vermueelen A, Verdonck L, Kaufman JM. A critical evaluation of simple methods for the estimation of free testosterone in serum. J Clin Endocrinol Metab. 1999; 84(10):3666–72. https://doi.org/10.1210/jcem.84.10.6079 PMID: 10523012

10. Powe CE, Evans MK, Wenger J, Zonderman AB, Berg AH, Nalls M, et al. Vitamin D-binding protein and vitamin D status of black Americans and white Americans. N Engl J Med. 2013; 369(21):1991–2000. https://doi.org/10.1056/NEJMoai306357 PMID: 24256378

11. Mendel CM. The free hormone hypothesis: a physiologically based mathematical model. Endocr Rev. 1989; 10(3):232–74. https://doi.org/10.1210/edrv-10-3-232 PMID: 2673754

12. Chun RF, Peery CE, Orwell ES, Nielson CM, Adams JS, Hewison M. Vitamin D and DBP: the free hormone hypothesis revisited. J Steroid Biochem Mol Biol. 2014; 144 Pt A:132–7. https://doi.org/10.1016/j.jsbmb.2013.09.012 PMID: 24095930

13. Christakos S, Dhawan P, Verstuyf A, Verlinden L, Carmeliet G. Vitamin D: Metabolism, Molecular Mechanism of Action, and Pleiotropic Effects. Physiol Rev. 2016; 96(1):365–408. https://doi.org/10.1152/physrev.00014.2015 PMID: 26681795

14. Nykjaer A, Dragun D, Walther D, Vorum H, Jacobsen C, Herz J, et al. An endocytic pathway essential for renal uptake and activation of the steroid 25-(OH) vitamin D3. Cell. 1999; 96(3):507–15. https://doi.org/10.1016/s0092-8674(00)80655-8 PMID: 10052453

15. Johnsen MS, Grimnes G, Figenschau Y, Torjesen PA, Almås B, Jorde R. Serum free and bio-available 25-hydroxyvitamin D correlate better with bone density than serum total 25-hydroxyvitamin D. Scand J Clin Lab Invest. 2014; 74(3):177–83. https://doi.org/10.3109/00365513.2013.869701 PMID: 24383929

16. Chhantyal K, He L, Halloran B, Kowalski MA, Ryzen E, Haddad JG. Assessment of the free fraction of 25-hydroxyvitamin D in serum and its regulation by albumin and the vitamin D-binding protein. J Clin Endocrinol Metab. 1986; 63(4):945–9. https://doi.org/10.1210/jcem-63-4-954 PMID: 3745048

17. Allison RJ, Farooq A, Cherif A, Hamilton B, Close GL, Wilson MG. Why don’t serum vitamin D concentrations associate with BMD by DXA? A case of being “bound” to the wrong assay? Implications for vitamin D screening. Br J Sports Med. 2018; 52(8):522–6. https://doi.org/10.1136/bjsports-2016-097130 PMID: 28798036

18. Michaelsson K, Rasmusson A, Wolk A, Byberg L, Mitchell A, Melhus H. The Free Hormone Hypothesis: Is Free Serum 25-Hydroxyvitamin D a Better Marker for Bone Mineral Density in Older Women? JBMR Plus. 2018; 2(6):367–74. https://doi.org/10.1002/jbmp4.10059 PMID: 30460340

19. Berg AH, Powe CE, Evans MK, Wenger J, Ortiz G, Zonderman AB, et al. 24,25-Dihydroxyvitamin D3 and vitamin D status of community-dwelling black and white Americans. Clin Chem. 2015; 61(6):877–84. https://doi.org/10.1373/clinchem.2015.240051 PMID: 25922442

20. Lee YA, Kim JY, Kang MJ, Chung SJ, Shin CH, Yang SW. Adequate vitamin D status and adiposity contribute to bone health in peripubertal nonobese children. Bone Miner Metab. 2013; 31(3):337–45. https://doi.org/10.1007/s00774-012-0419-4 PMID: 23371560

21. Ko D-H, Jun S-H, Nam Y, Song SH, Han M, Yun Y-M, et al. Multiplex LC–MS/MS for simultaneous determination of 25-hydroxyvitamin D, 24,25-dihydroxyvitamin D3, albumin, and vitamin D-binding protein with its isoforms: One-step estimation of bioavailable vitamin D and vitamin D metabolite ratio. The Journal of Steroid Biochemistry and Molecular Biology. 2021; 206:105796. https://doi.org/10.1016/j.jsbmb.2020.105796 PMID: 33299938

22. Moon JS, Lee SY, Nam CM, Choi J-M, Cho B-K, Seo J-W, et al. 2007 Korean National Growth Charts: review of developmental process and an outlook. Korean J Pediatr. 2008; 51(1):1–25. Available from: https://www.e-esp.org/journal/view.php?number=2008510101

23. Park S-H, Kim S-N, Lee SH, Choe J-S, Choi Y. Development of 9th Revision Korean Food Composition Table and Its Major Changes. Korean J Community Nutr. 2018; 23(4):352–65.
24. The Korean Nutrition Society (2015) Dietary reference intakes for Koreans. Available at [https://www.nibiohn.go.jp/eiken/kenkounippon21/download_files/foreign/foreign_kijun_korea.pdf](https://www.nibiohn.go.jp/eiken/kenkounippon21/download_files/foreign/foreign_kijun_korea.pdf) (Accessed May 2020).

25. U.S. Department of Health and Human Services (2018) 2018 physical activity guidelines for Americans: 2nd edition. [cited May, 2020]. Available from: [http://www.health.gov/paguidelines](http://www.health.gov/paguidelines).

26. Ross AC, Manson JE, Abrams SA, Aloia JF, Brannon PM, Clinton SK, et al. The 2011 report on dietary reference intakes for calcium and vitamin D from the Institute of Medicine: what clinicians need to know. J Clin Endocrinol Metab. 2011; 96(1):53–8. [https://doi.org/10.1210/jc.2010-2704 PMID: 21118827]

27. Lim JS, Hwang JS, Lee JA, Kim DH, Park KD, Cheon GJ, et al. Bone mineral density according to age, bone age, and pubertal stages in Korean children and adolescents. J Clin Densitom. 2010; 13(1):68–76. [https://doi.org/10.1016/j.jcd.2009.09.006 PMID: 19942470]

28. Lim JS, Hwang JS, Cheon GJ, Lee JA, Kim DH, Park KD, et al. Gender differences in total and regional body composition changes as measured by dual-energy x-ray absorptiometry in Korean children and adolescents. J Clin Densitom. 2009; 12(2):229–37. [https://doi.org/10.1016/j.jcd.2008.12.008 PMID: 19211284]

29. Nielson CM, Jones KS, Chun RF, Jacobs JM, Wang Y, Hewison M, et al. Free 25-Hydroxyvitamin D: Impact of Vitamin D Binding Protein Assays on Racial-Genotypic Associations. J Clin Endocrinol Metab. 2016; 101(5):2226–34. [https://doi.org/10.1210/jc.2016-1104 PMID: 27007693]

30. Jones G, Kaufmann M. Vitamin D metabolite profiling using liquid chromatography-tandem mass spectrometry (LC-MS/MS). J Steroid Biochem Mol Biol. 2016; 164:110–4. [https://doi.org/10.1016/j.jsbmb.2015.09.026 PMID: 26409684]

31. Wise SA, Phinney KW, Tai SS, Camara JE, Myers GL, Durazo-Arvizu R, et al. Baseline Assessment of 25-Hydroxyvitamin D Assay Performance: A Vitamin D Standardization Program (VDSP) Interlaboratory Comparison Study. J AOAC Int. 2017; 100(5):1244–52. [https://doi.org/10.5740/jaoacint.17-0258 PMID: 2882355]

32. Matsumoto H, Matsu K, Ishida N, Ohkura K, Teng YS. The distribution of Gc subtypes among the mongoloid populations. Am J Phys Anthropol. 1980; 53(4):505–8. [https://doi.org/10.1002/ajpa.1300530406 PMID: 7468786]

33. Peris P, Filella X, Monegal A, Guitart N, Foj L, Bonet M, et al. Concordance between direct and indirect measurements of free 25-OH vitamin D. Clin Chim Acta. 2017; 475:169–71. [https://doi.org/10.1016/j.cca.2017.10.016 PMID: 29056531]

34. Bolland MJ, Grey AB, Ames RW, Mason BH, Horne AM, Gamble GD, et al. Determinants of vitamin D status in older men living in a subtropical climate. Osteoporos Int. 2006; 17(12):1742–8. [https://doi.org/10.1007/s00198-006-0190-2 PMID: 16932872]

35. Gutiérrez Medina S, Gavela-Pérez T, Domínguez-Garrido MN, Gutiérrez-Moreno E, Rovira A, Gómez C, et al. The influence of puberty on vitamin D status in obese children and the possible relation between vitamin D deficiency and insulin resistance. J Pediatr Endocrinol Metab. 2015; 28(1–2):105–10. [https://doi.org/10.1515/jpem-2014-0033 PMID: 25153219]

36. Wortsman J, Matsuo LA, Chen TC, Lu Z, Holick MF. Decreased bioavailability of vitamin D in obesity. Am J Clin Nutr. 2000; 72(3):690–3. [https://doi.org/10.1093/ajcn/72.3.690 PMID: 10966885]

37. Marquina C, Mousa A, Scragg R, de Courten B. Vitamin D and cardiometabolic disorders: a review of current evidence, genetic determinants and pathomechanisms. Obesity Reviews. 2019; 20(2):262–77. [https://doi.org/10.1111/obr.12793 PMID: 30450683]

38. Bikle D, Bouillon R, Thadthi N, Schoenmaker I. Vitamin D metabolites in captivity? Should we measure free or total 25(OH)D to assess vitamin D status? J Steroid Biochem Mol Biol. 2017; 173:105–16. [https://doi.org/10.1016/j.jsbmb.2017.01.007 PMID: 28093353]

39. Carpenter TO, Zhang JH, Parra E, Ellis BK, Simpson C, Lee WM, et al. Vitamin D binding protein is a key determinant of 25-hydroxyvitamin D levels in infants and toddlers. J Bone Miner Res. 2013; 28(1):213–21. [https://doi.org/10.1002/jbmr.1735 PMID: 22887780]

40. Bouillon R. Pauwels S. The vitamin D-binding protein. In: Feldman D, Pike JW, Bouillon R, Giovannucci E, Goldzman D, Hewison M, eds. Vitamin D (4th Edition). London: Elsevier; 2018:97–115; 2018.

41. Simpson CA, Zhang JH, Vanderschueren D, Fu L, Pennestri TC, Bouillon R, et al. Relationship of Total and Free 25-Hydroxyvitamin D to Biomarkers and Metabolic Indices in Healthy Children. J Clin Endocrinol Metab. 2020; 105(4):e1631–40. [https://doi.org/10.1210/clinem/dgz230 PMID: 31774125]

42. Solid ST, Hutchinson MY, Berg V, Fuskevá OM, Figenschau Y, Thorsby PM, et al. Effects of vitamin D binding protein phenotypes and vitamin D supplementation on serum total 25(OH)D and directly measured free 25(OH)D. Eur J Endocrinol. 2016; 174(4):445–52. [https://doi.org/10.1530/EJE-15-1089 PMID: 26734479]
43. Henderson CM, Fink SL, Bassyouni H, Argiropoulos B, Brown L, Laha TJ, et al. Vitamin D-Binding Protein Deficiency and Homozygous Deletion of the GC Gene. N Engl J Med. 2019; 380(12):1150–7. https://doi.org/10.1056/NEJMoa1807841 PMID: 30893535

44. Jemielita TO, Leonard MB, Baker J, Sayed S, Zemel BS, Shults J, et al. Association of 25-hydroxyvitamin D with areal and volumetric measures of bone mineral density and parathyroid hormone: impact of vitamin D-binding protein and its assays. Osteoporos Int. 2016; 27(2):617–26. https://doi.org/10.1007/s00198-015-3296-6 PMID: 26359185

45. Michigami T. Skeletal mineralization: mechanisms and diseases. Ann Pediatr Endocrinol Metab. 2019; 24(4):213–9. https://doi.org/10.6065/apem.2019.24.4.213 PMID: 31905439

46. Lieben L, Carmeliet G. Vitamin D signaling in osteocytes: effects on bone and mineral homeostasis. Bone. 2013; 54(2):237–43. https://doi.org/10.1016/j.bone.2012.10.007 PMID: 23072922

47. Safadi FF, Thornton P, Magiera H, Hollis BW, Gentile M, Haddad JG, et al. Osteopathy and resistance to vitamin D toxicity in mice null for vitamin D binding protein. J Clin Invest. 1999; 103(2):239–51. https://doi.org/10.1172/JCI5244 PMID: 9916136

48. Bosworth CR, Levin G, Robinson-Cohen C, Hoofnagle AN, Ruzinski J, Young B, et al. The serum 24,25-dihydroxyvitamin D concentration, a marker of vitamin D catabolism, is reduced in chronic kidney disease. Kidney Int. 2012; 82(6):693–700. https://doi.org/10.1038/ki.2012.193 PMID: 22648296

49. Ginsberg C, Katz R, de Boer IH, Kestenbaum BR, Chonchol M, Shlipak MG, et al. The 24,25 to 25-hydroxyvitamin D ratio and fracture risk in older adults: The cardiovascular health study. Bone. 2018; 107:124–30. https://doi.org/10.1016/j.bone.2017.11.011 PMID: 29155243